72 related articles for article (PubMed ID: 21747120)
1. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Zauderer MG; Drilon A; Kadota K; Huberman K; Sima CS; Bergagnini I; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Riely GJ; Kris MG; Krug LM; Pietanza MC
Lung Cancer; 2014 Nov; 86(2):237-40. PubMed ID: 25194640
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
[TBL] [Abstract][Full Text] [Related]
4. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Cecchini M; Zhang JY; Wei W; Sklar J; Lacy J; Zhong M; Kong Y; Zhao H; DiPalermo J; Devine L; Stein SM; Kortmansky J; Johung KL; Bindra RS; LoRusso P; Schalper KA
Cancer Res Commun; 2023 Jun; 3(6):1132-1139. PubMed ID: 37387791
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas.
Coyne GO; Kummar S; Meehan RS; Do K; Collins JM; Anderson L; Ishii K; Takebe N; Zlott J; Juwara L; Piekarz R; Streicher H; Sharon E; Rubinstein L; Voth AR; Lozier J; Dull AB; Wilsker D; Hinoue T; Laird PW; Ferry-Galow KV; Kinders RJ; Parchment RE; Doroshow JH; Chen AP
Oncotarget; 2020 Nov; 11(44):3959-3971. PubMed ID: 33216844
[TBL] [Abstract][Full Text] [Related]
6. The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.
Fang Q
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254819
[TBL] [Abstract][Full Text] [Related]
7. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.
Querfeld C; Rosen ST; Guitart J; Duvic M; Kim YH; Dusza SW; Kuzel TM
Blood; 2014 Feb; 123(8):1159-66. PubMed ID: 24335103
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma
Silva-Hirschberg C; Hartman H; Stack S; Swenson S; Minea RO; Davitz MA; Chen TC; Schönthal AH
Ther Adv Med Oncol; 2019; 11():1758835919891567. PubMed ID: 31839810
[TBL] [Abstract][Full Text] [Related]
9. A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability.
Lewis DJ; Duvic M
JAAD Case Rep; 2017 Jul; 3(4):358-361. PubMed ID: 28761921
[No Abstract] [Full Text] [Related]
10. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.
Rao S; Beckman RA; Riazi S; Yabar CS; Boca SM; Marshall JL; Pishvaian MJ; Brody JR; Madhavan S
Oncotarget; 2017 Jun; 8(23):37923-37934. PubMed ID: 27888622
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of patients with mycosis fungoides after interferon α2b treatment failure.
Chmielowska E; Studziński M; Giebel S; Krause A; Olejniczak M; Grzanka A
Postepy Dermatol Alergol; 2015 Apr; 32(2):67-72. PubMed ID: 26015774
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
Jiang G; Li RH; Sun C; Liu YQ; Zheng JN
PLoS One; 2014; 9(12):e111920. PubMed ID: 25502446
[TBL] [Abstract][Full Text] [Related]
13. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Fan CH; Liu WL; Cao H; Wen C; Chen L; Jiang G
Cell Death Dis; 2013 Oct; 4(10):e876. PubMed ID: 24157870
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T-cell lymphomas: a review of new discoveries and treatments.
Bloom T; Kuzel TM; Querfeld C; Guitart J; Rosen ST
Curr Treat Options Oncol; 2012 Mar; 13(1):102-21. PubMed ID: 22311555
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
16. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract][Full Text] [Related]
17. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Castro GN; Cayado-Gutiérrez N; Zoppino FC; Fanelli MA; Cuello-Carrión FD; Sottile M; Nadin SB; Ciocca DR
Cell Stress Chaperones; 2015 Mar; 20(2):253-65. PubMed ID: 25155585
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
19. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
